2023

​

Activation of EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer

Ofra Novoplansky, Avital Shnerb, Divya Sree Marripati, Jonathan Zorea, Manu Prasad, Talal Ben-Lulu, Ragda Abu Sharb, Ksenia Yegodayev,  Chen Benafsha, Luc Morris, Ina Kurth, Jochen Hess and Moshe Elkabets. Inpress 

​

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in cancer patients.

Bar Kaufman, Orli Abramov, Anna Ievko, Daria Apple, Mark Shlapobersky, Irit Alon, Yariv Greenshpan, Baisali Bhattachrya, Tatiana Charkovsky, Alexandra Gayster, Ruthy Shaco-LevyPI, Keren RouvinovPI, Alejandro LiboffPI, Moshe ElkabetsPI*#, Angel PorgadorPI#.

2023 April Science Advance.

​

TRAF3 Suppression Encourages B Cell Recruitment and Prolongs Survival of Microbiome-Intact Mice with Ovarian Cancer

Jonathan Zorea, Yair Motro, Roei D. Mazor, Yifat Koren Carmi, Ziv Shulman, Jamal Mahajna, Jacob Moran-Gilad PI and Moshe Elkabets1,2PI . 2023 . April Journal of Experimental & Clinical Cancer Research

​

Metastasis of HRAS Mutated Head and Neck Tumors Requires YAP1-AXL Activation

Sankar Jagadeeshan1,2, Manu Prasad1,2, Mai Badarni1,2, Vijayasteltar Belsamma Liju1,2, Sooraj Mathukkada1,2, Claire Saunders1,2, Talal Ben Lulu1,2, Avital Beeri Shnerb1.2, Jonathan Zorea1,2, Ksenia M Yegodayev1,2, Monica Wainer1,2, Liza Vtorov1,2, Irit Allon2,3, Gro Gausdal4, Dinorah Friedmann-Morvinski5,6, Sok Ching Cheong 7,8, Alan L Ho9, Ari J Rosenberg10, Linda Kessler11, Francis Burrows11, Dexin Kong12, Jennifer R Grandis13, J Silvio Gutkind14, and Moshe Elkabets1,2 . Accepted – Cancer Research

 

Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair.

Xin Peng, Yingying Wang, Shaolu Zhang, Zhennan Tao, Yuxiang Dai, Francois X. Claret, Moshe Elkabets, Hou-Wen Lin, and Zhe-Sheng Chen, Dexin Kong. Signal Transduction and Targeted Therapy

​

2022

 

Stellettin B sensitizes glioblastoma to DNA-damaging treatments by suppressing PI3K-mediated homologous recombination repair.

Peng X, Zhang S, Wang Y, Zhou Z, Yu Z, Zhong Z, Zhang L, Chen ZS, Claret FX, Elkabets M, Wang F, Sun F, Wang R, Liang H, Lin HW, Kong D. Advanced Science (Weinh). 2023 Jan;

 

NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs.

Iraqi M, Bolel P, Sarkar R, Bhattacharya B, Abu Ahmad M, Edri A, Roisman LC, Elkabets M, Shalata W, Peled N, Porgador A. Int J Mol Sci. 2022 Nov  14;

​

The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor Microenvironment

Greenshpan Y, Sharabi O, Yegodayev KM, Novoplansky O, Elkabets M, Gazit R, Porgador A. Int J Mol Sci. 2022 Jul 4

​

Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis

Ofra Novoplansky, Sankar Jagadeeshan, Ohad Regev, Idan Menashe and Moshe Elkabets. Front Oncol. 2022 May 6

 

Crizotinib Restored Pembrolizumab Response in Advanced Non-Small Cell Lung Cancer

Laila C. Roisman#1, Nir Peled*1, Kiran Kundu2,3, Susmita Ghosh3 , Jonah M. Cooper4 , Walid Shalata5 , Yehonatan Aharon Cohen5 , Moshe Elkabets2 , Angel Porgador2,3, Waleed Kian#1, Ariel Sobarzo#2. . European Journal of Respiratory Medicine 2022

​

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital Shnerb, Jebrane Bouaoud, Lucas Michon, Ofra Novoplansky, Mai Badarni, Limor Cohen, Ksenia Yagodayev, Sapir Tzadok, Barak Rotblat, Libor Brezina, Andreas Mock, Andy Karabajakian, Jérôme Fayette, Idan Cohen, Tomer Cooks, Irit Allon, Orr Dimitstei, Benzion Joshua, Dexin Kong, Elena Voronov, Maurizio Scaltriti, Yaron Carmi, Jochen Hess, Luc G.T. Morris, Pierre Saintigny, and Moshe Elkabets. .–JOURNAL FOR IMMUNOTHERAPY OF CANCER 2022 Mar

​

Assessment of Parathyroid gland Cellularity by Digital Slide Analysis 

Rotem Sagiv, Bertha Delgado,Oleg Lavon, Vladislav Osipov, Re'em Sade,  Sagi Shashar, M Yegodayev, Moshe Elkabets, Ben-Zion Joshua. . Annals of Diagnostic Pathology 2022  Jun

​

 

 

2021​

 

Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy

Peng X, Zhang S, Jiao W, Zhong Z, Yang Y, Claret FX, Elkabets M, Wang F, Wang R, Zhong Y, Chen ZS, Kong D.J Exp Clin Cancer Res. 2021 Nov 29;40(1):374. doi: 10.1186/s13046-021-02176-2.

 

High parathyroid hormone levels after parathyroidectomy for parathyroid adenoma are not related to the cellularity of the remaining glands

Sagiv R, Delgado B, Sadeh R, Shashar S, Fraenkel M, Yegodayev KM, Elkabets M, Joshua BZ.Laryngoscope Investig Otolaryngol. 2021 Sep 8;6(5):1220-1227. doi: 10.1002/lio2.644. eCollection 2021 Oct.

 

Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCs

Jayaram DR, Frost S, Argov C, Liju VB, Anto NP, Muraleedharan A, Ben-Ari A, Sinay R, Smoly I, Novoplansky O, Isakov N, Toiber D, Keasar C, Elkabets M, Yeger-Lotem E, Livneh E.Proc Natl Acad Sci U S A. 2021 Oct 5;118(40):e2018899118. doi: 10.1073/pnas.2018899118. Epub 2021 Sep 30.

 

Cell stiffness predicts cancer cell sensitivity to ultrasound as a selective superficial cancer therapy

Bergman E, Goldbart R, Traitel T, Amar-Lewis E, Zorea J, Yegodayev K, Alon I, Rankovic S, Krieger Y, Rousso I, Elkabets M, Kost J.Bioeng Transl Med. 2021 May 27;6(3):e10226. doi: 10.1002/btm2.10226. eCollection 2021 Sep.

​

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)

Shalata W, Iraqi M, Bhattacharya B, Fuchs V, Roisman LC, Cohen AY, Massalha I, Yakobson A, Prasad M, Elkabets M, Porgador A, Peled N..Cancers (Basel). Cancers (Basel). 2021 Jul 20;13(14):3630. doi: 10.3390/cancers13143630..

​

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.

Badarni M, Prasad M, Golden A, Bhattacharya B, Levin L, Yegodayev KM, Dimitstein O, Joshua BZ, Cohen L, Khrameeva E, Kong D, Porgador A, Braiman A, Grandis JR, Rotblat B, Elkabets M.Cancers (Basel). 2021 May 7;13(9):2250. doi: 10.3390/cancers13092250.PMID: 34067117 Free PMC article.

​

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair.

Zhang S, Peng X, Li X, Liu H, Zhao B, Elkabets M, Liu Y, Wang W, Wang R, Zhong Y, Kong D.Cell Death Dis. 2021 May 26;12(6):546. doi: 10.1038/s41419-021-03805-6.PMID: 34039959 Free PMC article.

​

José Baselga M.D., Ph.D. (1959-2021) leading cancer researcher and oncologist.

Elkabets M, Blandino G.J Exp Clin Cancer Res. 2021 May 7;40(1):156. doi: 10.1186/s13046-021-01966-y.PMID: 33962670 Free PMC article. No abstract available.

​

KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix.

Kim JK, Marco MR, Choi SH, Qu X, Chen CT, Elkabets M, Fairchild L, Chow O, Barriga FM, Dow LE, O'Rourke K, Szeglin B, Yarilin D, Fujisawa S, Manova-Todorova K, Paty PB, Shia J, Leslie C, Joshua Smith J, Lowe S, Pelossof R, Sanchez-Vega F, Garcia-Aguilar J.Mol Oncol. 2021 Apr 4. doi: 10.1002/1878-0261.12960. Online ahead of print.PMID: 33817986 Free article.

​

The 4-NQO mouse model: An update on a well-established in vivo model of oral carcinogenesis.

Bouaoud J, De Souza G, Darido C, Tortereau A, Elkabets M, Bertolus C, Saintigny P.Methods Cell Biol. 2021;163:197-229. doi: 10.1016/bs.mcb.2020.09.004. Epub 2020 Nov 12.PMID: 33785166

​

Quaternized Starch-Based Composite Nanoparticles for siRNA Delivery to Tumors

Eliz Amar-Lewis, Nitsa Buaron, Ramesh Chintakunta, Chen Benafsha, Riki Goldbart, Tamar Traitel, Manu Prasad, Moshe Elkabets, Joseph Kost. ACS Applied Nano Materials 2021

​

Using Free-Range Laboratory Mice to Explore Foraging, Lifestyle, and Diet Issues in Cancer

Douglas F Makin, Ella Agra, Manu Prasad, Joel S Brown, Moshe Elkabets, Jorge Fernando Saraiva Menezes, Franklin Sargunaraj, Burt P Kotler. Frontiers in Ecology and Evolution 2021

​

Synthetic promoters to induce immune-effectors into the tumor microenvironment.

Greenshpan Y, Sharabi O, Ottolenghi A, Cahana A, Kundu K, M Yegodayev K, Elkabets M, Gazit R, Porgador A.Commun Biol. 2021 Jan 29;4(1):143. doi: 10.1038/s42003-021-01664-7.PMID: 33514819 Free PMC article.

​

EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.

Alsahafi EN, Thavaraj S, Sarvestani N, Novoplansky O, Elkabets M, Ayaz B, Tavassoli M, Legends MF.Cancer Lett. 2021 Feb 1;498:80-97. doi: 10.1016/j.canlet.2020.10.035. Epub 2020 Oct 31.PMID: 33137407

​

2020

​

CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3Kα Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.

Remer E, Badarni M, Hikri E, Dayan A, Levi L, Popovtzer A, Iraqi M, Porgador A, Joshua BZ, Bachar G, Elkabets M, Scaltriti M, Mizrachi A.J Clin Med. 2020 Oct 7;9(10):3214. doi: 10.3390/jcm9103214.PMID: 33036331 Free PMC article.

​

 

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.

Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, Novoplansky O, Jagadeeshan S, Liao Y, Rix U, Misale S, Taylor BS, Bardelli A, Hechtman JF, Hyman DM, Elkabets M, de Stanchina E, Verma CS, Ventura A, Drilon A, Scaltriti M.Cancer Discov. 2021 Jan;11(1):126-141. doi: 10.1158/2159-8290.CD-20-0571. Epub 2020 Oct 1.PMID: 33004339 Free PMC article.

​

​

​

Surface roughness-induced absorption acts as an ovarian cancer cells growth sensor-monitor.

Katiyi A, Zorea J, Halstuch A, Elkabets M, Karabchevsky A.Biosens Bioelectron. 2020 Aug 1;161:112240. doi: 10.1016/j.bios.2020.112240. Epub 2020 Apr 25.PMID: 32365013

​

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer.

Yegodayev KM, Novoplansky O, Golden A, Prasad M, Levin L, Jagadeeshan S, Zorea J, Dimitstein O, Joshua BZ, Cohen L, Khrameeva E, Elkabets M.Cancers (Basel). 2020 Feb 3;12(2):339. doi: 10.3390/cancers12020339.PMID: 32028632 Free PMC article.

​

Probing antibody surface density and analyte antigen incubation time as dominant parameters influencing the antibody-antigen recognition events of a non-faradaic and diffusion-restricted electrochemical immunosensor.

Zorea J, Shukla RP, Elkabets M, Ben-Yoav H.Anal Bioanal Chem. 2020 Mar;412(7):1709-1717. doi: 10.1007/s00216-020-02417-x. Epub 2020 Jan 29.PMID: 31996962 Free PMC article.

​

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System.

Prasad M, Jagadeeshan S, Scaltriti M, Allon I, Elkabets M.J Vis Exp. 2020 Jan 9;(155). doi: 10.3791/60410.PMID: 31984965

​

Potential oncogenic roles of mutant-p53-derived exosomes in the tumor-host interaction of head and neck cancers.

Azulay EE, Cooks T, Elkabets M.Cancer Immunol Immunother. 2020 Feb;69(2):285-292. doi: 10.1007/s00262-019-02450-5. Epub 2020 Jan 3.PMID: 31897662 Review.

​

​

2019

​

Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations.

Jagadeeshan S, Prasad M, Ortiz-Cuaran S, Gregoire V, Saintigny P, Elkabets M.Trends Cancer. 2019 Jun;5(6):365-390. doi: 10.1016/j.trecan.2019.04.004. Epub 2019 May 28.PMID: 31208698 Review.

​

Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.

Kundu K, Ghosh S, Sarkar R, Edri A, Brusilovsky M, Gershoni-Yahalom O, Yossef R, Shemesh A, Soria JC, Lazar V, Joshua BZ, Campbell KS, Elkabets M, Porgador A.Cancer Immunol Res. 2019 Jul;7(7):1120-1134. doi: 10.1158/2326-6066.CIR-19-0023. Epub 2019 Jun 4.PMID: 31164357 Free PMC article.

​

c-Met as a new marker of cellular senescence.

Boichuck M, Zorea J, Elkabets M, Wolfson M, Fraifeld VE.Aging (Albany NY). 2019 May 13;11(9):2889-2897. doi: 10.18632/aging.101961.PMID: 31085799 Free PMC article.

​

The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells.

Varon M, Levy T, Mazor G, Ben David H, Marciano R, Krelin Y, Prasad M, Elkabets M, Pauck D, Ahmadov U, Picard D, Qin N, Borkhardt A, Reifenberger G, Leprivier G, Remke M, Rotblat B.Int J Cancer. 2019 Dec 15;145(12):3402-3413. doi: 10.1002/ijc.32400. Epub 2019 Jun 12.PMID: 31081944

​

Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.

Badarni M, Prasad M, Balaban N, Zorea J, Yegodayev KM, Joshua BZ, Dinur AB, Grénman R, Rotblat B, Cohen L, Elkabets M.JCI Insight. 2019 Mar 12;5(8):e125341. doi: 10.1172/jci.insight.125341.PMID: 30860495 Free PMC article.

​

Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy.

Ghosh S, Prasad M, Kundu K, Cohen L, Yegodayev KM, Zorea J, Joshua BZ, Lasry B, Dimitstein O, Bahat-Dinur A, Mizrachi A, Lazar V, Elkabets M, Porgador A.Front Oncol. 2019 Jan 22;9:17. doi: 10.3389/fonc.2019.00017. eCollection 2019.PMID: 30723707 Free PMC article.

​

High-Throughput Screening Identified Compounds Sensitizing Tumor Cells to Glucose Starvation in Culture and VEGF Inhibitors In Vivo.

Marciano R, Prasad M, Ievy T, Tzadok S, Leprivier G, Elkabets M, Rotblat B.Cancers (Basel). 2019 Jan 30;11(2):156. doi: 10.3390/cancers11020156.PMID: 30704052 Free PMC article.

​

MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.

Novoplansky O, Fury M, Prasad M, Yegodayev K, Zorea J, Cohen L, Pelossof R, Cohen L, Katabi N, Cecchi F, Joshua BZ, Popovtzer A, Baselga J, Scaltriti M, Elkabets M.Int J Cancer. 2019 Aug 1;145(3):748-762. doi: 10.1002/ijc.32170. Epub 2019 Feb 11.PMID: 30694565 Free PMC article.

​

Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?

Ben-Aharon I, Elkabets M, Pelossof R, Yu KH, Iacubuzio-Donahue CA, Leach SD, Lowery MA, Goodman KA, O'Reilly EM.Clin Cancer Res. 2019 Apr 1;25(7):2185-2193. doi: 10.1158/1078-0432.CCR-18-3042. Epub 2019 Jan 7.PMID: 30617137 Free PMC article.

​

​

​

​

2018

​

​

IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer.

Zorea J, Prasad M, Cohen L, Li N, Schefzik R, Ghosh S, Rotblat B, Brors B, Elkabets M.Cell Death Dis. 2018 Sep 20;9(10):944. doi: 10.1038/s41419-018-1025-8.PMID: 30237504 Free PMC article.

​

Methods to Study the Role of Progranulin in the Tumor Microenvironment.

Elkabets M, Brook S.Methods Mol Biol. 2018;1806:155-176. doi: 10.1007/978-1-4939-8559-3_12.PMID: 29956276

​

Enhanced ZnR/GPR39 Activity in Breast Cancer, an Alternative Trigger of Signaling Leading to Cell Growth.

Ventura-Bixenshpaner H, Asraf H, Chakraborty M, Elkabets M, Sekler I, Taylor KM, Hershfinkel M.Sci Rep. 2018 May 25;8(1):8119. doi: 10.1038/s41598-018-26459-5.PMID: 29802348 Free PMC article.

​

​

2017

​

​

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.

Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J.Science. 2017 Mar 24;355(6331):1324-1330. doi: 10.1126/science.aah6893.PMID: 28336670 Free PMC article.

​

​

2016

​

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.

Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, Adler K, Baut E, Scaltriti M, Jena PV, Gardner EE, Poirier JT, Rudin CM, Baselga J, Haimovitz-Friedman A, Heller DA.Sci Transl Med. 2016 Jun 29;8(345):345ra87. doi: 10.1126/scitranslmed.aaf7374.PMID: 27358497 Free PMC article.

​

Streptococcus pneumoniae fructose-1,6-bisphosphate aldolase, a protein vaccine candidate, elicits Th1/Th2/Th17-type cytokine responses in mice.

Elhaik Goldman S, Dotan S, Talias A, Lilo A, Azriel S, Malka I, Portnoi M, Ohayon A, Kafka D, Ellis R, Elkabets M, Porgador A, Levin D, Azhari R, Swiatlo E, Ling E, Feldman G, Tal M, Dagan R, Mizrachi Nebenzahl Y.Int J Mol Med. 2016 Apr;37(4):1127-38. doi: 10.3892/ijmm.2016.2512. Epub 2016 Mar 1.PMID: 26935978

​

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.

Scaltriti M, Elkabets M, Baselga J.Clin Cancer Res. 2016 Mar 15;22(6):1313-7. doi: 10.1158/1078-0432.CCR-15-1458. Epub 2016 Jan 13.PMID: 26763248 Free PMC article. Review.

​

​

2015

​

​

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J.Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.PMID: 25873175 Free PMC article.

​

​

2014

​

Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M.Mol Cell Oncol. 2014 Oct 29;1(3):e963447. doi: 10.4161/23723548.2014.963447. eCollection 2014 Jul-Sep.PMID: 27308344 Free PMC article. Review.

​

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.

Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M.Sci Signal. 2014 Mar 25;7(318):ra29. doi: 10.1126/scisignal.2005125.PMID: 24667376 Free PMC article.

​

​

2013

​

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J.Sci Transl Med. 2013 Jul 31;5(196):196ra99. doi: 10.1126/scitranslmed.3005747.PMID: 23903756 Free PMC article.

​

Unique Versus Redundant Functions of IL-1α and IL-1β in the Tumor Microenvironment.

Voronov E, Dotan S, Krelin Y, Song X, Elkabets M, Carmi Y, Rider P, Idan Cohen, Romzova M, Kaplanov I, Apte RN.Front Immunol. 2013 Jul 8;4:177. doi: 10.3389/fimmu.2013.00177. eCollection 2013.PMID: 23847618 Free PMC article.

​

​

2006-2012

​

The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talk.

Elhaik-Goldman S, Kafka D, Yossef R, Hadad U, Elkabets M, Vallon-Eberhard A, Hulihel L, Jung S, Ghadially H, Braiman A, Apte RN, Mandelboim O, Dagan R, Mizrachi-Nebenzahl Y, Porgador A.PLoS One. 2011;6(8):e23472. doi: 10.1371/journal.pone.0023472. Epub 2011 Aug 22.PMID: 21887255 Free PMC article.

​

Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis.

Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN.J Immunol. 2011 Mar 15;186(6):3462-71. doi: 10.4049/jimmunol.1002901. Epub 2011 Feb 7.PMID: 21300825 Free article.

​

Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice.

Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirström K, Magnusson K, Ebert BL, Pontén F, Weinberg RA, McAllister SS.J Clin Invest. 2011 Feb;121(2):784-99. doi: 10.1172/JCI43757. Epub 2011 Jan 25.PMID: 21266779 Free PMC article.

​

IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA.Eur J Immunol. 2010 Dec;40(12):3347-57. doi: 10.1002/eji.201041037.PMID: 21110318 Free PMC article.

​

Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting.

Cohen M, Elkabets M, Perlmutter M, Porgador A, Voronov E, Apte RN, Lichtenstein RG.J Immunol. 2010 Nov 15;185(10):5869-78. doi: 10.4049/jimmunol.1001635. Epub 2010 Oct 18.PMID: 20956342 Free article.

​

Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin.

Sarfati G, Dvir T, Elkabets M, Apte RN, Cohen S.Biomaterials. 2011 Jan;32(1):152-61. doi: 10.1016/j.biomaterials.2010.09.014. Epub 2010 Oct 14.PMID: 20889205

​

IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice.

Voronov E, Dotan S, Gayvoronsky L, White RM, Cohen I, Krelin Y, Benchetrit F, Elkabets M, Huszar M, El-On J, Apte RN.Int Immunol. 2010 Apr;22(4):245-57. doi: 10.1093/intimm/dxq006. Epub 2010 Feb 24.PMID: 20181656

​

Differences in the sialylation patterns of membrane stress proteins in chemical carcinogen-induced tumors developed in BALB/c and IL-1alpha deficient mice.

Avidan A, Perlmutter M, Tal S, Oraki O, Kapp T, Krelin Y, Elkabets M, Dotan S, Apte RN, Lichtenstein RG.Glycoconj J. 2009 Dec;26(9):1181-95. doi: 10.1007/s10719-009-9238-9.PMID: 19430902

​

Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells.

Elkabets M, Krelin Y, Dotan S, Cerwenka A, Porgador A, Lichtenstein RG, White MR, Zoller M, Iwakura Y, Dinarello CA, Voronov E, Apte RN.J Immunol. 2009 Apr 15;182(8):4874-81. doi: 10.4049/jimmunol.0803916.PMID: 19342666

​

Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors.

Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN.Cancer Res. 2007 Feb 1;67(3):1062-71. doi: 10.1158/0008-5472.CAN-06-2956.PMID: 17283139

​

The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.

Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E.Cancer Metastasis Rev. 2006 Sep;25(3):387-408. doi: 10.1007/s10555-006-9004-4.PMID: 17043764 Review.

​

Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions.

Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, Segal S, Voronov E.Eur J Cancer. 2006 Apr;42(6):751-9. doi: 10.1016/j.ejca.2006.01.010. Epub 2006 Mar 10.PMID: 16530403 Review.

​

Differential effects of monastrol in two human cell lines.

Leizerman I, Avunie-Masala R, Elkabets M, Fich A, Gheber L.Cell Mol Life Sci. 2004 Aug;61(16):2060-70. doi: 10.1007/s00018-004-4074-3.PMID: 15316655

​

​